Amazon's Reported $7.5 Billion Decart Deal Tests Its AI Spending Strategy
Amazon's reported $7.5 billion Decart deal could test whether mega-cap AI spending remains durable during an AI-sector sell-off.
Oruka Therapeutics Insider Sale Puts Clinical-Stage Biotech Sentiment Under the Microscope
Oruka’s $853,985 insider sale draws attention as traders weigh the transaction against positive EVER…
Viatris Wins FDA Approval for Neurontin Supplement as Legacy Franchise Remains in Focus
Viatris’ Neurontin supplemental submission SUPPL-60 received FDA approval, highlighting regulatory p…
PMV Pharma Shares in Focus After Rezatapopt Data Sets Up Q1 2027 FDA Filing
PMV’s updated rezatapopt data show a 36% response rate across 168 evaluable patients, with a potenti…
PMV Pharmaceuticals’ Updated Rezatapopt Data Puts Precision Oncology Back in Focus
PMV Pharmaceuticals’ updated PYNNACLE Phase 2 data gives investors a closer look at rezatapopt and i…
Revolution Medicines Defies Market Selloff as Survival Data Lift RVMD
RVMD traded higher as survival data, a $226 William Blair target and new Phase 3 treatment activity …
Belite Bio Slides 12% as FDA Extends Tinlarebant Review
Belite Bio shares fell 12% after the FDA extended its tinlarebant review by three months, resetting …
Savara Shares Slip After FDA Delays Autoimmune PAP Decision
Savara’s missed FDA target date leaves investors facing a longer wait for clarity on its autoimmune …
Revolution Medicines Rallies on Clinical Data as Biotech Decouples From Weak Market
Revolution Medicines showed premarket relative strength as clinical data offset a 1.0% S&P 500 decli…
Capricor Therapeutics Defies Market Selloff as Traders Position for FDA Catalyst
CAPR rallied in premarket trading as the Nasdaq and S&P 500 declined, putting the biotech’s FDA cata…